MXPA01001995A - Aza-biciclos que modulan la inhibicion de adhesion celular. - Google Patents

Aza-biciclos que modulan la inhibicion de adhesion celular.

Info

Publication number
MXPA01001995A
MXPA01001995A MXPA01001995A MXPA01001995A MXPA01001995A MX PA01001995 A MXPA01001995 A MX PA01001995A MX PA01001995 A MXPA01001995 A MX PA01001995A MX PA01001995 A MXPA01001995 A MX PA01001995A MX PA01001995 A MXPA01001995 A MX PA01001995A
Authority
MX
Mexico
Prior art keywords
linkage
ny4y5
alkyl
compounds
ny1y2
Prior art date
Application number
MXPA01001995A
Other languages
English (en)
Inventor
Clive Mccarthy
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818641.4A external-priority patent/GB9818641D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of MXPA01001995A publication Critical patent/MXPA01001995A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invencion esta dirigida a compuestos fisiologicamente activos de formula I, en donde R1 representa R3-Z3-, R3-L2-R4Z3-, R3-L3-Ar1-L4-Z3- o R3-L3-Ar1-L2-R4-Z3-, R2 representa hidrogeno, halogeno, alquilo inferior o alcoxi inferior; A1 representa un enlace de alquileno de C1-3 de cadena recta opcionalmente sustituido por uno o mas grupos elegidos de alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, imino, oxo, tioxo o alquilo sustituido por -ZR6, -NY1Y2, -CO2R6 o -C(=O)-NY1Y2; L1 representa un enlace directo; un enlace alquenileno, alquileno, alquinileno, cicloalquenileno, cicloalquileno, heteroarildiilo, heterocicloalquileno o arileno, cada uno opcionalmente sustituido por (a) un grupo funcional acido, ciano, oxo, -S(O)mR9, R3, -C(=O)-R3, -C(=O)-OR3, -N(R8)-C(=O)-R9, - N(R8)-C(=O)-OR9,-N(R8)-S02-R9 - NY4Y5 o -[C(=O)-N(R10)-C(R5)(R11)]p-C(=O)-NY4Y5, o (b) alquilo sustituido por un grupo funcional acido, o por S(O)m,R9, -C(=O)-NY4Y5 o -NY4Y5; un enlace -[C(=O)- N(R10)-C(R5)(R11)]p; un enlace -Z2-R12-; un enlace -C(=O)-CH2-C(=O)-; un enlace -R12-Z2-R12-; un enlace -C(R4)(R13)-[C(=O)-N(R10)-C(R5)(R11)]p-; o un enlace -L5 -L6 -L7-; Z1 es C(R7)(R7a). C(=O) o CH(OH); Y es carboxi o un bioisostero acido, y los N-oxidos correspondientes, y sus profarmacos, y sales farmaceuticamente aceptables y solvatos de dichos compuestos y sus N-oxidos y profarmacos; dichos compuestos tienen propiedades farmaceuticas valiosas, en particular la capacidad para regular la interaccion de VCAM-1 y fibronectina con la integrina VLA-4 (a4??1).
MXPA01001995A 1998-08-26 1999-08-26 Aza-biciclos que modulan la inhibicion de adhesion celular. MXPA01001995A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818641.4A GB9818641D0 (en) 1998-08-26 1998-08-26 Chemical compounds
US11000898P 1998-11-25 1998-11-25
PCT/GB1999/002819 WO2000015612A1 (en) 1998-08-26 1999-08-26 Aza-bicycles which modulate the inhibition of cell adhesion

Publications (1)

Publication Number Publication Date
MXPA01001995A true MXPA01001995A (es) 2004-07-30

Family

ID=26314269

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01001995A MXPA01001995A (es) 1998-08-26 1999-08-26 Aza-biciclos que modulan la inhibicion de adhesion celular.

Country Status (21)

Country Link
US (1) US6608084B1 (es)
EP (1) EP1114028B1 (es)
KR (1) KR20010085630A (es)
CN (1) CN1323295A (es)
AT (1) ATE346841T1 (es)
AU (1) AU754557B2 (es)
BR (1) BR9913222A (es)
CA (1) CA2341677A1 (es)
DE (1) DE69934238T2 (es)
DK (1) DK1114028T3 (es)
ES (1) ES2276530T3 (es)
HU (1) HUP0104766A3 (es)
IL (2) IL141596A0 (es)
MX (1) MXPA01001995A (es)
NO (1) NO20010942L (es)
NZ (1) NZ509781A (es)
PL (1) PL346248A1 (es)
PT (1) PT1114028E (es)
SK (1) SK2612001A3 (es)
TR (1) TR200100588T2 (es)
WO (1) WO2000015612A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60009480T2 (de) * 1999-05-05 2005-09-01 Aventis Pharma Ltd., West Malling Harnstoffe als modulatoren der zelladhäsion
SK8692002A3 (en) 1999-12-28 2003-06-03 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2001235806A1 (en) * 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
CA2427750C (en) 2000-11-04 2011-01-04 Aventis Pharma Limited Substituted alkanoic acids
WO2002053534A1 (fr) 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs de vla-4
IL159203A0 (en) * 2001-06-06 2004-06-01 Aventis Pharma Ltd Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
WO2003011815A1 (en) * 2001-07-26 2003-02-13 Celltech R & D Limited Bicyclic heteroaromatic alanines
RU2315041C2 (ru) * 2002-04-30 2008-01-20 ЮСиБи, С.А. Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения
KR100767854B1 (ko) 2003-03-12 2007-10-17 화이자 프로덕츠 인크. 피리딜옥시메틸 및 벤즈이속사졸 아자비시클릭 유도체
CA2528586A1 (en) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
KR20080021085A (ko) 2005-06-09 2008-03-06 유씨비 파마, 에스.에이. 2，6 퀴놀리닐 유도체, 이들을 제조하는 방법 및 이들의약제로서의 용도
US7790745B2 (en) * 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US20090111828A1 (en) * 2005-11-23 2009-04-30 Astrazeneca Ab L-alanine derivatives
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
JP5733841B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド 神経学的および精神的障害の治療のための複素環式化合物
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
WO2011084851A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
WO2011084850A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs for the treatment of schizophrenia and bipolar disease
WO2011084849A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
ES2647361T3 (es) * 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
AU2010339691B2 (en) 2010-01-07 2015-04-02 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8894846B2 (en) * 2010-12-23 2014-11-25 Stephen Lee Yarbro Using supercritical fluids to refine hydrocarbons
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
SG11201604795RA (en) 2013-12-20 2016-07-28 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
MX2016012041A (es) 2014-03-20 2017-01-19 Alkermes Pharma Ireland Ltd Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
BR112021007213A2 (pt) 2018-10-30 2021-08-10 Gilead Sciences, Inc. derivados de quinolina como inibidores de integrina alfa4beta7
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1497118A1 (de) * 1965-05-29 1969-04-17 Agfa Gevaert Ag Sensibilisierte elektrophotographische Schichten
ZA814057B (en) * 1980-06-18 1982-07-28 May & Baker Ltd Indole and indoline derivatives
EP0422298B1 (en) * 1989-10-12 1994-12-21 International Business Machines Corporation Display system
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU4080597A (en) * 1996-08-23 1998-03-06 Board Of Regents For Oklahoma State University, The Heteroarotinoids-anticancer agents with receptor specificity and tgase activity
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten

Also Published As

Publication number Publication date
SK2612001A3 (en) 2001-11-06
NZ509781A (en) 2003-05-30
NO20010942L (no) 2001-04-19
KR20010085630A (ko) 2001-09-07
PT1114028E (pt) 2007-02-28
CN1323295A (zh) 2001-11-21
WO2000015612A1 (en) 2000-03-23
DE69934238D1 (de) 2007-01-11
PL346248A1 (en) 2002-01-28
NO20010942D0 (no) 2001-02-23
ES2276530T3 (es) 2007-06-16
ATE346841T1 (de) 2006-12-15
EP1114028A1 (en) 2001-07-11
IL141596A (en) 2006-07-05
HUP0104766A2 (hu) 2002-04-29
BR9913222A (pt) 2001-10-16
TR200100588T2 (tr) 2001-08-21
CA2341677A1 (en) 2000-03-23
DE69934238T2 (de) 2007-06-21
US6608084B1 (en) 2003-08-19
HUP0104766A3 (en) 2002-08-28
EP1114028B1 (en) 2006-11-29
AU5634399A (en) 2000-04-03
DK1114028T3 (da) 2007-04-30
IL141596A0 (en) 2002-03-10
AU754557B2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
MXPA01001995A (es) Aza-biciclos que modulan la inhibicion de adhesion celular.
TR200400401T4 (tr) Nitrojen-değişimli aminotetralinlerin hazırlanması için geliştirilmiş yöntem
ATE263162T1 (de) Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren
TW200604558A (en) (Meth)acrylamide monomers containing hydroxy and silicone functionalities
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
AP2000001924A0 (en) Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines.
IL145748A0 (en) Substituted bicyclic heteroaryl compounds as integrin antagonists
DE60041487D1 (de) Substituierte bizyclische verbindungen
ATE120465T1 (de) Tumorhemmende saccharid-konjugate.
ATE229526T1 (de) Pyranone, verfahren zu ihrer herstellung und verwendung
NO940019L (no) Fremgangsmåte for fremstilling av svovelholdige imidazolderivater
DE69500274D1 (de) Thiazin- oder Thiomorpholinderivate
EA200000876A1 (ru) Дигидробензо(1,4)оксазины и тетрагидрохиноксалины
WO1993004059A1 (en) 4-acylaminoimidazole derivative
HU9301415D0 (en) Octahydro-naphtaline-oxime derivatives inhibiting biological synthesis of cholesterol
EA200001077A2 (ru) Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции
NO930679L (no) Tetrahydrotiofenderivater
TW363967B (en) Bisquaternary ammonium compound of 2,2'- dimethyl-l, l'-binaphthyl and process for their preparation
YU71501A (sh) Supstituisana biciklična heteroaril jedinjenja kao antagonisti integrina
DK0868428T3 (da) Phosphonsyrederivater med metallopeptidaseinhiberende aktivitet
NO944762L (no) Nye 3-okso-1,4-benzotiazinderivater
NO975150L (no) Fremgangsmåte for fremstilling av enantiomere former av aminoalkylaminofenylpropansyre
CA2019005A1 (en) Antiherpes pentapeptide derivatives having a cycloalkyl substituted aspartic acid side chain

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees